Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Northern Trust Corp

Northern Trust Corp grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 979,137 shares of the company’s stock after acquiring an additional 112,847 shares during the quarter. Northern Trust Corp owned about 0.96% of Intellia Therapeutics worth $11,417,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after acquiring an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new position in Intellia Therapeutics during the 4th quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics during the 4th quarter worth $43,000. Jones Financial Companies Lllp lifted its holdings in shares of Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares during the period. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock valued at $60,000 after buying an additional 2,299 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright assumed coverage on Intellia Therapeutics in a report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price objective for the company. Wells Fargo & Company cut their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 28th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. The Goldman Sachs Group restated a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Finally, Chardan Capital restated a “buy” rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $36.90.

Intellia Therapeutics Trading Up 5.3%

Shares of Intellia Therapeutics stock opened at $8.50 on Friday. The stock has a 50-day moving average price of $8.00 and a 200 day moving average price of $10.82. The company has a market cap of $880.46 million, a P/E ratio of -1.56 and a beta of 2.33. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analysts’ expectations of $11.39 million. The firm’s revenue was down 42.6% on a year-over-year basis. During the same period in the prior year, the company posted ($1.12) earnings per share. On average, equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.